Neurotransmitter interactions related to central dopamine neurons.
D000109:Acetylcholine / Q000378:metabolism / Q000502:physiology; D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000378:metabolism / Q000502:physiology*; D002490:Central Nervous System / Q000502:physiology; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism; D007980:Levodopa / Q000009:adverse effects; D001523:Mental Disorders / Q000378:metabolism; D009434:Neural Pathways / Q000502:physiology; D009474:Neurons / Q000378:metabolism / Q000502:physiology*; D018377:Neurotransmitter Agents / Q000378:metabolism / Q000502:physiology*; D009638:Norepinephrine / Q000502:physiology; D010275:Parasympathetic Nervous System / Q000502:physiology; D010300:Parkinson Disease / Q000378:metabolism; D012701:Serotonin / Q000502:physiology; D005680:gamma-Aminobutyric Acid / Q000502:physiology
D014150:Antipsychotic Agents; D018377:Neurotransmitter Agents; D012701:Serotonin; D007980:Levodopa; D005680:gamma-Aminobutyric Acid; D000109:Acetylcholine; D004298:Dopamine; D009638:Norepinephrine